PolarityTE, Inc.
PTE · NASDAQ Capital Market · USD
0,241USD
−0,002 (−0,82 %)Stand 15. Juni, 20:00
Kennzahlen
- Eröffnung
- 0,2377
- Vortag
- 0,243
- Tagesspanne
- 0,23 – 0,2534
- 52 Wochen
- 0,20 – 1,90
- Volumen
- 8,32 Mio.
- Ø Volumen
- 446.876
- Börsenwert
- 1,78 Mio. $
- KGV
- –
- Gewinn je Aktie (TTM)
- –
- Dividendenrendite
- –
- Beta
- 1,2
- Nächste Zahlen
- –
Finanzen
Gerade nicht verfügbar.
Bewertung
Gerade nicht verfügbar.
Analysten
Einstufungen
Gerade nicht verfügbar.
Kursziel
Gerade nicht verfügbar.
Quartalszahlen
Gerade nicht verfügbar.
Dividenden und Splits
Gerade nicht verfügbar.
Aktiensplits
Gerade nicht verfügbar.
Eigentümer
Institutionen
Gerade nicht verfügbar.
Insider-Geschäfte
Gerade nicht verfügbar.
Vergleichbare Unternehmen
Gerade nicht verfügbar.
Über das Unternehmen
Based in Salt Lake City, Utah, PolarityTE, Inc. is a clinical-stage biotechnology company focused on the development and commercialization of regenerative tissue products and biomaterials. Its offerings serve the medical, biomedical engineering, and material sciences sectors across the United States. The company operates through two primary divisions: Regenerative Medicine Products and Contract Services. PolarityTE's key product is SkinTE, a specialized tissue solution employed for the repair, reconstruction, replacement, or augmentation of skin in patients. Its applications encompass treating acute or chronic wounds, burns, surgical reconstruction, scar revision, and the removal of dysfunctional skin grafts. In addition to its product line, the firm also provides contract research services. The company's pipeline includes SkinTE Cryo, which facilitates multiple deployments from a single harvest through a cryopreservation process, and a SkinTE point-of-care device designed for immediate processing and application of SkinTE directly after initial harvest. PolarityTE is also advancing PTE 11000, an allogenic, biologically active dressing engineered to accelerate healing in both wound care and aesthetic contexts, alongside other promising tissue regeneration products.
- CEO
- Richard Hague
- Mitarbeitende
- 42
- Hauptsitz
- Salt Lake City, UT, US
- Sektor
- Healthcare
- Branche
- Biotechnology
- Börsengang
- 16. Aug. 1999
- Website
- polaritybio.com
Nachrichten
Gerade nicht verfügbar.
Kurse mindestens 15 Minuten verzögert. Daten: Financial Modeling Prep. Keine Anlageberatung.